WallStreetZenWallStreetZen

NYSE: RBOT
VICARIOUS SURGICAL INC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for RBOT

Based on 5 analysts offering 12 month price targets for VICARIOUS SURGICAL INC.
Min Forecast
$5.00+32.28%
Avg Forecast
$13.20+249.21%
Max Forecast
$16.00+323.28%

Should I buy or sell RBOT stock?

Based on 5 analysts offering ratings for VICARIOUS SURGICAL INC.
Buy
Strong Buy
2 analysts 40%
Buy
2 analysts 40%
Hold
1 analysts 20%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

RBOT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Piper Sandler
Top 38%
63
HoldMaintains$5.00+32.28%2022-05-10
Credit Suisse
Bottom 12%
12
BuyInitiates Coverage On$16.00+323.28%2022-01-07
Cowen & Co.
Top 26%
75
BuyInitiates Coverage On$15.00+296.83%2021-12-07
Canaccord Genuity
Top 15%
86
Strong BuyInitiates Coverage On$15.00+296.83%2021-11-05
BTIG
Top 5%
96
Strong BuyInitiates Coverage On$15.00+296.83%2021-10-18

1 of 1

Forecast return on equity

Is RBOT forecast to generate an efficient return?
Company
-40.66%
Industry
27.24%
Market
32.71%
RBOT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RBOT forecast to generate an efficient return on assets?
Company
-28.97%
Industry
14.27%
RBOT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RBOT earnings per share forecast

What is RBOT's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.60
Avg 2 year Forecast
-$0.69
Avg 3 year Forecast
-$0.90

RBOT revenue forecast

What is RBOT's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$119.0M
Avg 2 year Forecast
$120.0M
Avg 3 year Forecast
$292.0M

RBOT vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
RBOT$3.78$13.20+249.21%Buy
SIBN$12.92$30.50+136.07%Strong Buy
OWLT$3.85$7.58+96.96%Hold
MASS$15.31$30.00+95.95%Buy
MDXG$3.61$15.75+336.29%Buy
View Top Medical Device Stocks

VICARIOUS SURGICAL Stock Forecast FAQ

Is VICARIOUS SURGICAL Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: RBOT) stock is to Buy RBOT stock.

Out of 5 analysts, 2 (40%) are recommending RBOT as a Strong Buy, 2 (40%) are recommending RBOT as a Buy, 1 (20%) are recommending RBOT as a Hold, 0 (0%) are recommending RBOT as a Sell, and 0 (0%) are recommending RBOT as a Strong Sell.

What is RBOT's earnings growth forecast for 2022-2024?

(NYSE: RBOT) VICARIOUS SURGICAL's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 24.11%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.

VICARIOUS SURGICAL's earnings in 2022 is $12,551,000.On average, 2 Wall Street analysts forecast RBOT's earnings for 2022 to be -$72,746,746, with the lowest RBOT earnings forecast at -$73,959,192, and the highest RBOT earnings forecast at -$71,534,300. On average, 2 Wall Street analysts forecast RBOT's earnings for 2023 to be -$83,658,758, with the lowest RBOT earnings forecast at -$84,871,204, and the highest RBOT earnings forecast at -$82,446,312.

In 2024, RBOT is forecast to generate -$109,120,119 in earnings, with the lowest earnings forecast at -$109,120,119 and the highest earnings forecast at -$109,120,119.

What is RBOT's revenue growth forecast for 2024-2026?

(NYSE: RBOT) VICARIOUS SURGICAL's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.29%.

VICARIOUS SURGICAL's revenue in 2022 is $0.On average, 1 Wall Street analysts forecast RBOT's revenue for 2024 to be $14,428,104,663, with the lowest RBOT revenue forecast at $14,428,104,663, and the highest RBOT revenue forecast at $14,428,104,663. On average, 1 Wall Street analysts forecast RBOT's revenue for 2025 to be $14,549,349,240, with the lowest RBOT revenue forecast at $14,549,349,240, and the highest RBOT revenue forecast at $14,549,349,240.

In 2026, RBOT is forecast to generate $35,403,416,484 in revenue, with the lowest revenue forecast at $35,403,416,484 and the highest revenue forecast at $35,403,416,484.

What is RBOT's forecast return on assets (ROA) for 2022-2025?

(NYSE: RBOT) forecast ROA is -28.97%, which is lower than the forecast US Medical Devices industry average of 14.27%.

What is RBOT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year RBOT price target, the average RBOT price target is $13.20, with the highest RBOT stock price forecast at $16.00 and the lowest RBOT stock price forecast at $5.00.

On average, Wall Street analysts predict that VICARIOUS SURGICAL's share price could reach $13.20 by May 10, 2023. The average VICARIOUS SURGICAL stock price prediction forecasts a potential upside of 249.21% from the current RBOT share price of $3.78.

What is RBOT's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: RBOT) VICARIOUS SURGICAL's current Earnings Per Share (EPS) is -$0.89. On average, analysts forecast that RBOT's EPS will be -$0.60 for 2022, with the lowest EPS forecast at -$0.61, and the highest EPS forecast at -$0.59. On average, analysts forecast that RBOT's EPS will be -$0.69 for 2023, with the lowest EPS forecast at -$0.70, and the highest EPS forecast at -$0.68. In 2024, RBOT's EPS is forecast to hit -$0.90 (min: -$0.90, max: -$0.90).

What is RBOT's forecast return on equity (ROE) for 2022-2025?

(NYSE: RBOT) forecast ROE is -40.66%, which is considered weak.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending StocksStock Market SectorsStock Market Industries
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.